News

Data from a Phase 3 clinical trial showed that patients with pulmonary arterial hypertension (PAH) might benefit from selexipag treatment, as the drug was seen to lower the risk of death or PAH-related complications. The study, published in the New England Journal of Medicine, is titled “Selexipag for the…

SteadyMed, Ltd., a company that develops products to treat orphan and high-value conditions with unmet parenteral delivery needs, recently announced that its lead product candidate, Trevyent® has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).

Reata Pharmaceuticals, Inc., recently announced the enrollment of the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in its LARIAT study, a Phase 2 clinical trial assessing the safety, efficacy, and tolerability of bardoxolone methyl in patients with pulmonary hypertension (PH). PH is characterized by unusually high…

According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization, under orphan drug designation. PAH is a life-threatening disease…

Team PHenomenal Hope will take part in a seven-day cycling competition to raise awareness of pulmonary hypertension (PH) and money to advance research into the disease. The nonprofit, presented by the University of Pittsburgh Medical Center (UPMC), Bayer Healthcare, and Actelion, is competing in the The Pioneer race through New Zealand’s Southern Alps.

Sildenafil (Revatio) — a phosphodiesterase type-5 inhibitor developed by Pfizer – is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Two large international clinical trials, the STARTS I and II trials, subsequently investigated the safety of sildenafil use in children. Based on their findings, however, the U.S. Food and Drug Administration (FDA) and the…

Pulmonary Hypertension News has covered news surrounding the latest treatments, events, clinical trials, and research updates related to pulmonary hypertension on a daily basis throughout the past year. As the year of 2015 comes to an end, our “Top 10 Most Read Pulmonary Hypertension Articles of 2015” ranks the…

Researchers in Turkey evaluated the two drug therapy approaches commonly used to treat pulmonary arterial hypertension (PAH) and found no substantial difference between the two in the patients observed. The study, titled “Combination Therapy in Pulmonary Arterial Hypertension: Single Centre Long-term Experience“ appeared in May 2015 in the West…

Boehringer Ingelheim recently announced the enrollment of the first patient in its global, double-blind, randomized, and placebo-controlled SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) Phase 3 clinical trial. The trial (NCT02597933) is now enrolling patients, and is evaluating the safety and the efficacy of nintedanib in patients with systemic sclerosis (SSc)…

Researchers from Japan described ways to predict the progression and severity of pulmonary hypertension (PH) in people with left heart disease. Their paper, a review of standard and emerging methods for assessing the lung disease, is titled “The Roles of Classic and Current Prognostic Factors in Pulmonary Hypertension Due…

German President Joachim Gauck has awarded the 2015 Deutscher Zukunftspreis, which honors innovation in science and technology, to a pulmonary hypertension (PH) research team that discovered and developed a drug effective in the treatment of two serious types of the disease. The winning team — led by Professor Ardeschir Ghofrani from the University Clinic…

Eiger BioPharmaceuticals, Inc. recently announced in a press release that a Notice of Allowance from the United States Patent and Trademark Office (USPTO) has been issued for the U.S. patent application 13/829,321, titled “Treatment of Pulmonary Hypertension with Leukotriene Inhibitors” covering Bestatin™ (ubenimex), a leukotriene A4hydrolase (LTA4H) inhibitor, for treating…